FIRST AMENDMENT OF EXCLUSIVE TECHNOLOGY OPTION AGREEMENTExclusive Technology Option Agreement • November 12th, 2009 • Omeros Corp • Pharmaceutical preparations • Moca
This amendment (this “Amendment”) serves to amend the Exclusive Technology Option Agreement dated September 4, 2008 between Omeros Corporation (“Omeros”), Patobios Limited (“Patobios”), Susan R. George, M.D., Brian F. O’Dowd, Ph.D. and U.S. Bank National Association (the “Agreement”) and is effective as of November 10, 2009. Except as expressly set forth below, capitalized terms used and not redefined in this Amendment have the same meanings given to them in the Agreement.
EXCLUSIVE TECHNOLOGY OPTION AGREEMENTExclusive Technology Option Agreement • May 15th, 2009 • Omeros Corp • Pharmaceutical preparations • Washington
THIS EXCLUSIVE TECHNOLOGY OPTION AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2008 by and among Omeros Corporation, a Washington corporation (“Omeros”), Patobios Limited, a corporation incorporated under the laws of the Province of Ontario (“Patobios”), Susan R. George, M.D. (“Dr. George”) and Brian F. O’Dowd, Ph.D. (“Dr. O’Dowd”) and, with respect to Article VIII and Article X only, U.S. Bank National Association, as escrow agent (the “Escrow Agent”). Dr. George and Dr. O’Dowd are referred to herein each as a “Founder” and collectively as the “Founders.”
